Neuron for expressing human Tau as well as preparation method and application of neuron
By constructing engineered induced pluripotent stem cells carrying human Tau genes, the problem that in vitro models in the existing technology cannot simulate the Tau expression pattern of the adult brain is solved, and the rapid and convenient preparation of neurons expressing human Tau is achieved. Study Tau protein pathology and drug screening for neurodegenerative diseases.
Patent Information
- Application Number
- CN202410360296.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-27
- Publication Date
- 2024-12-03
AI Technical Summary
The existing in vitro neuronal models cannot effectively simulate the Tau expression pattern in the adult brain. The preparation process is complex, the cycle is long and the stability is low, making it difficult to meet the needs of Tau protein pathology and drug development.
By constructing engineered pluripotent stem cells carrying human Tau genes, Ngn2 and FUdeltaGW-rtTA genes were introduced, and expression was induced by doxycin, and rapidly differentiated into neurons expressing human Tau, simulated Tau expression in the human brain model.
Achieve rapid and convenient preparation of human Tau expressing neurons, which can efficiently simulate the Tau expression pattern of the adult brain, and provide a more reliable cellular tool for studying Tau protein pathology and drug screening for neurodegenerative diseases. .
Smart Images

Figure CN119060959A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field and relates to a neuron expressing human Tau and a preparation method and application thereof. Background Art
[0002] Tau protein is a microtubule-associated protein that participates in microtubule assembly, stability, and axonal transport. The human Tau gene is located on chromosome 17 and consists of 16 exons that are alternatively spliced to produce six different Tau isoforms. These isoforms differ in that there are 3 or 4 tandem repeats (3R and 4R) in the carboxyl-terminal region, and 0 (0N), 29 (1N), or 58 (2N) amino acid insertions in the amino-terminal portion of the protein. In the human fetal brain, only the shortest isoform 0N3R is expressed, while in the normal adult brain, all six Tau isoforms (0N3R, 1N3R, 2N3R, 0N4R, 1N4R, and 2N4RTau.) are present, and the ratio between the 3R and 4R isoforms is approximately 1:1. In a variety of neurodegenerative diseases, Tau protein can undergo a variety of abnormal post-translational modifications, such as hyperphosphorylation, followed by oligomerization and development into neurofibrillary tangles, ultimately leading to neuronal apoptosis. According to the type of Tau protein in the aggregate, Tau diseases can be divided into three categories: 3R+4R Tau diseases (such as Alzheimer's disease), 3R Tau diseases (such as Pick's disease), and 4R Tau diseases (such as progressive supranuclear palsy and corticobasal degeneration). The construction of Tau disease neuronal models in vitro is of great significance for the study of disease mechanisms and drug development.
[0003] With the invention and widespread application of induced pluripotent stem cell (iPSC) technology, methods for inducing iPSC to differentiate into neurons have gradually emerged, making it possible to obtain a large number of humanized neurons. However, cell reprogramming changes the expression of many genes in the cell, returning the cell to a state similar to the early developmental stage. Therefore, iPSC-derived neurons may represent the developmental stage of the fetus, and their 4R Tau expression level is significantly lower than that of adult brain neurons, which cannot well reflect the Tau pathology of adult neurodegenerative diseases in scientific research. Primary neuron culture technology is another common technology for obtaining neurons. It is usually enzymatically digested from the embryonic cerebral cortex or hippocampus of mice or rats and then inoculated into well plates for culture. However, there are certain differences between mouse Tau and human Tau sequences. In order to simulate the Tau expression pattern characteristics of the adult brain in an in vitro neuronal model, Jin Ming et al. extracted primary rat hippocampal neurons, transferred the human 2N4RTau gene by lentiviral infection after 4 hours of in vitro culture, and waited for the primary neurons to be cultured in vitro for about 21 days for the experiment. However, the method needs to infect lentivirus in each experiment, which has the disadvantages of difficulty in obtaining fetal mice, long experimental cycle, cumbersome operation and poor experimental stability.
[0004] In summary, the development of a method that can efficiently and conveniently obtain neurons that mimic the Tau expression pattern characteristics of the adult brain is of great significance in fields such as Tau protein pathology and drug development. Summary of the invention
[0005] In view of the deficiencies in the prior art and actual needs, the present invention provides a neuron expressing human Tau and a preparation method and application thereof, in order to solve the problems that the current in vitro models for studying Tau pathology usually cannot reflect the Tau expression pattern characteristics of the adult brain, as well as the complex preparation process, long cycle and low stability.
[0006] To achieve this object, the present invention adopts the following technical solutions:
[0007] In a first aspect, the present invention provides an engineered induced pluripotent stem cell carrying a human Tau gene, wherein the engineered induced pluripotent stem cell is an induced pluripotent stem cell containing a plasmid;
[0008] The plasmids include an inducible expression plasmid containing Ngn2 (neurogenin 2, NEUROG2) gene, FUdeltaGW-rtTA and a plasmid containing human Tau gene.
[0009] In the present invention, an inducible expression plasmid containing the Ngn2 (neurogenin 2, NEUROG2) gene, an inducible expression plasmid containing a fluorescent protein encoding gene, and a plasmid containing a human Tau gene are introduced into induced pluripotent stem cells to construct engineered induced pluripotent stem cells. Mature neurons capable of efficiently expressing human Tau protein can be prepared by inducing engineered induced pluripotent stem cells, thereby better simulating the Tau expression pattern of neurons in the adult brain.
[0010] Preferably, the induced pluripotent stem cells include human induced pluripotent stem cells.
[0011] Preferably, the starting plasmid of the plasmid containing the human Tau gene includes VSVG-LENTAI-Tet-O-FUW.
[0012] Preferably, the human Tau gene includes any one of the human 2N4RTau gene, the human 1N4RTau gene or the human 0N4RTau gene, or a combination of at least two of them.
[0013] It can be understood that any gene sequence encoding human Tau known in the art can be applied to the present invention.
[0014] Preferably, the starting plasmid of the inducible expression plasmid containing the Ngn2 gene includes pTet-O plasmid or Tet-O-FUW plasmid.
[0015] Preferably, the inducible expression plasmid containing the Ngn2 gene includes pTet-O-Ngn2-puro (Plasmid #52047).
[0016] In the present invention, the plasmid FUdeltaGW-rtTA contains a switch for regulating the expression of pTet-O-Ngn2-puro, which can be induced to express by doxycycline, and after expression, it can regulate the expression of pTet-O-Ngn2-puro; the expression of pTet-O-Ngn2-puro can initiate the transformation of engineered induced pluripotent stem cells into engineered neural cells, and can also make the cells resistant to puromycin, which is convenient for rapid screening of engineered neural cells.
[0017] In a second aspect, the present invention provides a neuron carrying a human Tau gene, wherein the neuron carrying a human Tau gene is derived from the engineered induced pluripotent stem cell carrying the human Tau gene described in the first aspect.
[0018] The neuronal cells carrying the human Tau gene are obtained by subjecting the engineered induced pluripotent stem cells carrying the human Tau gene described in the first aspect to antibiotic induction and screening followed by differentiation and culture.
[0019] In a third aspect, the present invention provides a method for preparing the engineered induced pluripotent stem cells carrying the human Tau gene according to the first aspect, the method comprising:
[0020] An inducible expression plasmid containing the Ngn2 gene, FUdeltaGW-rtTA and a plasmid containing the human Tau gene are introduced into induced pluripotent stem cells to obtain the engineered induced pluripotent stem cells carrying the human Tau gene.
[0021] In a fourth aspect, the present invention provides a method for preparing neurons carrying a human Tau gene according to the second aspect, the preparation method comprising:
[0022] The engineered induced pluripotent stem cells carrying the human Tau gene described in the first aspect are cultured in a culture medium containing antibiotics to obtain the neurons carrying the human Tau gene.
[0023] In the present invention, based on the designed engineered induced pluripotent stem cells carrying the human Tau gene, and further developing and preparing neurons carrying the human Tau gene, it is possible to conveniently and massively prepare neurons expressing human 2N4R Tau, and to efficiently express human Tau.
[0024] Preferably, the antibiotics include doxycycline and puromycin.
[0025] Preferably, the working concentration of doxycycline is 1-3 μg / mL, and the working concentration of puromycin is 0.3-0.7 μg / mL.
[0026] In a fifth aspect, the present invention provides the use of neurons carrying the human Tau gene described in the second aspect in constructing a model that simulates the Tau expression pattern characteristics of the human brain.
[0027] The present invention can rapidly prepare neurons carrying the human Tau gene, can efficiently express human Tau, and effectively simulate the Tau expression pattern of neurons in the adult brain, thereby providing a more reliable cell tool for studying the Tau protein pathology of neurodegenerative diseases.
[0028] In a sixth aspect, the present invention provides the use of neurons carrying the human Tau gene or a model constructed thereby as described in the second aspect in screening drugs for treating neurodegenerative diseases.
[0029] The present invention is based on neurons carrying human Tau genes and simulates the Tau expression pattern of neurons in the adult brain, and can be used for Tau protein pathology research of neurodegenerative diseases or screening of therapeutic drugs.
[0030] Compared with the prior art, the present invention has the following beneficial effects:
[0031] In view of the shortcomings of the current neuronal Tau expression pattern, the present invention constructs engineered induced pluripotent stem cells that inducibly express the Ngn2 gene and the human Tau gene based on induced pluripotent stem cells, which can be quickly induced and differentiated into neurons expressing human Tau, and can be easily prepared in large quantities, providing a more reliable cell tool for studying the Tau protein pathology of neurodegenerative diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 Flowchart for the preparation of neurons expressing human 2N4RTau;
[0033] Figure 2 This is an immunocytostaining image of neurons expressing human 2N4RTau;
[0034] Figure 3 The result diagram is the ratio of 4R Tau and total Tau fluorescence intensity;
[0035] Figure 4 This is the ratio of the fluorescent area of 4R Tau and total Tau. DETAILED DESCRIPTION
[0036] To further illustrate the technical means and effects of the present invention, the present invention is further described below in conjunction with the embodiments and drawings. It should be understood that the specific implementation methods described herein are only used to explain the present invention, rather than to limit the present invention.
[0037] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0038] The basic technical route in the specific embodiment of the present invention is as follows Figure 1 As shown, iPSCs were edited by viral infection and then induced into neural cells by doxycycline, including:
[0039] (1) pTet-O-Ngn2-puro (Plasmid #52047), FUdeltaGW-rtTA (Plasmid #19780), and Tet-O-htau2N4R (constructed by Shanghai Taiertu Biotechnology Co., Ltd.) plasmids were respectively transferred into viruses;
[0040] (2) After human induced pluripotent stem cells are revived and subcultured, the cells are seeded in multi-well plates and cultured using mTeSR1 medium (with added Rock inhibitor);
[0041] (3) The packaged virus is mixed with mTeSR1 medium at an appropriate MOI (determined by the virus infection effect. It is recommended to select the appropriate MOI after a preliminary virus gradient infection) and added to the cells. After infection, the medium containing the virus is aspirated and replaced with fresh mTeSR1. After that, new mTeSR1 medium is replaced every day until the cells cover the entire bottom of the well plate;
[0042] (4) Subculture until there are enough cells for use. Digest the cells with a mild cell dissociation reagent for 1 minute and then freeze some of the cells using CryoStorTM CS10 cell freezing medium. The cells can be subcultured within 10 generations.
[0043] (5) Another portion of cells was subcultured into a 10 cm cell culture dish and cultured using mTeSR1 (with Rock inhibitor) medium until the cells filled 60% to 80% of the dish.
[0044] (6) Replace the medium with KSR (with doxycycline) and culture.
[0045] (7) Replace the medium with KSR+N2B (with doxycycline and puromycin) and culture.
[0046] (8) Replace the medium with N2B (supplemented with doxycycline, puromycin and B27) and culture.
[0047] (9) After digesting the cells with Accutase, cryopreserved cells using NBM (supplemented with B27, Rock inhibitor, FBS, and DMSO);
[0048] (10) Resuscitate the cells obtained in step (9) according to experimental needs, and replace the culture medium every 4 days until the cells are differentiated and mature on about 21 days.
[0049] In a specific embodiment of the present invention, the basic formula of the relevant culture medium is shown in Table 1-Table 3.
[0050] Table 1 KSR medium (500 mL)
[0051]
[0052]
[0053] Table 2N2B culture medium (500 mL)
[0054] name content Part Number DMEM / F-12 medium 482.5mL Gibco#11330032 GlutaMAX(100×) 5mL Gibco#35050 20% Dextrose 7.5mL N2-supplement B (100×) 5mL StemCell#07156
[0055] Table 3 NBM culture medium (500 mL)
[0056]
[0057] Example 1
[0058] (1) Human induced pluripotent stem cells (RC01001-A, provided by the Stem Cell Bank of the Chinese Academy of Sciences) were revived and subcultured, and the cells were seeded in 6-well plates. mTeSR1 (+10 μM Rock inhibitor) medium was used, 2 mL per well, and cultured for 24 hours.
[0059] (2) pTet-O-Ngn2-puro (Plasmid #52047), FUdeltaGW-rtTA (Plasmid #19780) and Tet-O-htau2N4R (constructed by Shanghai Taiertu Biotechnology Co., Ltd., starting vector: VSVG-LENTAI-Tet-O-FUW-htau2N4R, htau2N4R sequence information: https: / / asia.ensembl.org / Homo_sapiens / Export / Output / Gene?db=core;flank3_display=0;flank5_display=0;g=ENSG00000276155;output=fasta;r=HSCHR17_1_CTG5:760287-893653;strand=feature;param=cdna;param=utr5;param=utr3;genomic=unmask ed;_format=HTML, search ENST00000621329.4, a gene fragment of 1326 bases, translated to obtain a sequence of 441 amino acids) vector packaged as lentivirus. The next day, the human induced pluripotent stem cells were replaced with mTeSR1 medium containing lentivirus and no Rock inhibitor, 2 mL per well. The MOI values of pTet-O-Ngn2-puro, FUdeltaGW-rtTA, and Tet-O-htau2N4R were 5, 2, and 3, respectively.
[0060] (3) 24 hours after infection, the virus-containing medium was aspirated and replaced with fresh mTeSR1. Thereafter, new mTeSR1 medium was replaced every 24 hours until the cells covered the entire bottom of the well plate.
[0061] (4) The cells were subcultured at a density of 1 to 6 in 10 cm cell culture dishes. 8 mL of mTeSR1 (+10 μM Rock inhibitor) medium was used per dish. The next day, the medium was replaced with fresh mTeSR1 medium without Rock inhibitor. Thereafter, new mTeSR1 medium was replaced every 24 hours until the cells covered the entire bottom of the dish.
[0062] (5) The cells were subcultured again at a density of 1 to 6 in 10 cm cell culture dishes, with 8 mL of mTeSR1 (+10 μM Rock inhibitor) medium per dish. The medium was replaced with fresh mTeSR1 without Rock inhibitor the next day, and thereafter, new mTeSR1 medium was replaced every 24 hours.
[0063] (6) After a portion of the cells in step (5) were spread over the entire bottom of the plate, the cells were digested with 2 mL of mild cell dissociation reagent per plate at room temperature for 1 minute, and frozen using CryoStorTM CS10 cell freezing solution, with a freezing density of 200 μL freezing solution / 2 million cells per cryopreservation tube. The cells were placed in a program freezing box and frozen at -80°C overnight, and transferred to a liquid nitrogen tank freezing box the next day to obtain induced pluripotent stem cells that can express human 2N4R Tau, named iPSC-htau2N4R cells.
[0064] Another portion of cells was used to prepare neurons expressing human 2N4RTau.
[0065] Example 2
[0066] In this example, neurons expressing human 2N4RTau were prepared.
[0067] Take a portion of the cells cultured in step (5) of Example 1 and culture until the cells cover about 80% of the plate. On the first day, replace the KSR (2 μg / mL doxycycline) medium, 8 mL per plate, and culture for 24 hours. On the second day, replace the KSR+N2B (2 μg / mL doxycycline and 0.5 μg / mL puromycin) medium with a volume ratio of 1:1, 8 mL per plate, and culture for 24 hours. On the third day, replace the N2B (2 μg / mL doxycycline, 0.5 μg / mL puromycin and 1% B-27 additive by volume) medium, 8 mL per plate, and culture for 24 hours. On the fourth day, 2 mL of cell digestion solution (Accutase) was used per dish to digest the cells at 37 ° C for 3 minutes, and the cells were frozen using NBM medium (added with 2% B-27 additive by volume, 10 μM Rock inhibitor, 40% fetal bovine serum by volume, and 10% dimethyl sulfoxide by volume). The freezing density was 200 μL of freezing solution / 2 million cells per cryopreservation tube. Place it in a program freezing box, freeze it at -80 ° C overnight, and transfer it to a liquid nitrogen tank freezing box the next day. Neurons expressing human 2N4R Tau were obtained by induction and named iN4-htau2N4R cells, where iN4 means 4 days of culture, and can be named in sequence according to different culture days, such as iN15-htau2N4R cells, which means neurons expressing human 2N4R Tau after continued culture for 15 days.
[0068] In addition, referring to the above method, the only difference is that the Tet-O-htau2N4 vector is replaced with an empty vector without the human 2N4RTau gene inserted, and neurons are induced and prepared, which is named iN4.
[0069] Example 3
[0070] iN4-htau2N4R and iN4 (control group, without human 2N4R Tau (htau2N4R)) were revived at a density of 10,000 cells per well in a 96-well plate and cultured in NBM (supplemented with 2% B27, 10 μM Rock inhibitor, 2 μg / mL doxycycline and 0.5 μg / mL puromycin) medium, 200 μL per well. Fresh NBM (supplemented with 2% B27, 2 μg / mL doxycycline and 0.5 μg / mL puromycin) medium was replaced after 4 days, and the medium was replaced every 4 days thereafter.
[0071] When the cells grew to iN15, they were fixed with paraformaldehyde, and then the 4R Tau and total Tau of the cells were stained using immune cell staining, and fluorescence images were collected using a confocal microscope.
[0072] Observe the confocal fluorescence images ( Figure 2 ) and quantitative analysis ( Figure 3 , Figure 4 ), the 4R Tau content of iN4-htau2N4R was significantly higher than that of the control group, confirming that iN4-htau2N4R successfully overexpressed 4R Tau with high maturity, indicating that the present invention successfully prepared neurons that simulated the Tau expression pattern of neurons in the adult brain.
[0073] In summary, the present invention aims at the shortcomings of the current neuronal Tau expression pattern. Based on induced pluripotent stem cells, engineered induced pluripotent stem cells that inducibly express the Ngn2 gene and the human 2N4RTau gene are constructed, which can be rapidly induced and differentiated into neurons expressing human 2N4RTau, and can be easily prepared in large quantities, providing a more reliable cell tool for studying the Tau protein pathology of neurodegenerative diseases.
[0074] The applicant declares that the present invention illustrates the detailed method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned detailed method, that is, it does not mean that the present invention must rely on the above-mentioned detailed method to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
Claims
1. An engineered induced pluripotent stem cell carrying a human Tau gene, characterized in that: The engineered induced pluripotent stem cells are induced pluripotent stem cells containing a plasmid; The plasmids include an inducible expression plasmid containing the Ngn2 gene, FUdeltaGW-rtTA and a plasmid containing the human Tau gene.
2. The engineered cell carrying the human Tau gene according to claim 1, characterized in that: The induced pluripotent stem cells include human induced pluripotent stem cells.
3. The engineered cell carrying the human Tau gene according to claim 1 or 2, characterized in that: The starting plasmid of the plasmid containing the human Tau gene includes VSVG-LENTAI-Tet-O-FUW; Preferably, the human Tau gene includes any one of the human 2N4RTau gene, the human 1N4RTau gene or the human 0N4RTau gene, or a combination of at least two thereof; Preferably, the starting plasmid of the inducible expression plasmid containing the Ngn2 gene includes pTet-O plasmid or Tet-O-FUW plasmid.
4. A neuron carrying a human Tau gene, characterized in that: The neurons carrying the human Tau gene are derived from the engineered induced pluripotent stem cells carrying the human Tau gene according to any one of claims 1 to 3; The neuronal cells carrying the human Tau gene are obtained by subjecting the engineered induced pluripotent stem cells carrying the human Tau gene according to any one of claims 1 to 3 to antibiotic induction and screening followed by differentiation and culture.
5. A method for preparing an engineered induced pluripotent stem cell carrying a human Tau gene according to any one of claims 1 to 3, characterized in that: The method comprises: An inducible expression plasmid containing the Ngn2 gene, FUdeltaGW-rtTA and a plasmid containing the human Tau gene are introduced into induced pluripotent stem cells to obtain the engineered induced pluripotent stem cells carrying the human Tau gene.
6. A method for preparing neurons carrying human Tau gene according to claim 4, characterized in that: The preparation method comprises: The engineered induced pluripotent stem cells carrying the human Tau gene according to any one of claims 1 to 3 are cultured in a culture medium containing antibiotics to obtain the neurons carrying the human Tau gene.
7. The method for preparing neurons carrying human Tau gene according to claim 6, characterized in that: The antibiotics include doxycycline and puromycin.
8. The method for preparing neurons carrying human Tau gene according to claim 7, characterized in that: The working concentration of doxycycline is 1-3 μg / mL, and the working concentration of puromycin is 0.3-0.7 μg / mL.
9. Use of the neurons carrying the human Tau gene according to claim 4 in constructing a model simulating the Tau expression pattern characteristics of the human brain.
10. Use of the neurons carrying the human Tau gene or the model constructed therefrom as claimed in claim 4 in screening drugs for treating neurodegenerative diseases.
